Recent trials of antithrombotics in the management of patients with acute coronary syndromes
- Robert A. Harrington MD
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
This is an exciting time to practice acute care cardiology as the tools of molecular biology are being used to discover multiple new therapies that affect the thrombotic system and may offer real benefit to patients. Correspondingly, the tools of information technology offer the real possibility that these new therapies can be rapidly and definitively studied in large outcome trials. Continued biologic discovery, coupled with reliable clinical trials methodology should allow clinicians to offer patients and society therapies with proven benefits and understood risks.
- Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997, 349:1269–1276. CrossRef
- Ross R: Atherosclerosis-an inflammatory disease. New Engl J Med 1999, 340:115–126. CrossRef
- Antiplatelet Trialists’ Collaboration: Collaborative overview of randomized trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994, 308:81–106.
- Oler A, Whooley MA, Oler J, Grady D: Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996, 276:811–815. CrossRef
- Ohman EM, Kleiman NS, Gacioch G, et al., for the IMPACTAMI Investigators: Combined accelerated tissue-plasminogen activator and platelet glycoprotein Iib/IIIa receptor blockade with Integrilin in acute myocardial infarction. Circulation 1997, 95:846–854.
- The PARADIGM Investigators: Combining thrombolysis with the platelet glycoprotein Iib/IIIa inhibitor lamifiban: Results of the PARADIGM trial. J Am Coll Cardiol 1998, 32:2003–2010. CrossRef
- Antman EM, Giugliano RP, Gibson CM, et al.: Abciximab facilitates the rate and extent of thrombolysis — Results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 1999, 99:2720–2732.
- Newby LK, Rutsch WR, Califf RM, et al., for the GUSTO-I Investigators. Time from symptom onset to treatment and outcomes after thrombolytic therapy. J Am Coll Cardiol. 1996, 27:1646–1655. CrossRef
- Kong DF, Califf RM, Miller DP, et al.: Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/ IIIa integrin in ischemic heart disease. Circulation 1998 98:2829–2835.
- Antman EM: TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallelgroup, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators. Am Heart J 1998, 135:S353-S360.
- Cohen M, Demers C, Gurfinkel EP, et al., for the ESSENCE Study Group: A comparison of low molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997, 337:447–452. CrossRef
- Recent trials of antithrombotics in the management of patients with acute coronary syndromes
Current Cardiology Reports
Volume 1, Issue 3 , pp 181-183
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, 27705, Durham, NC, USA